| Download the amazing global Makindo app: ✅ Means NICE/National Guidelines 2026 compliant Android | Apple | |
|---|---|
| MEDICAL DISCLAIMER: Educational use only. Not for diagnosis or management. See below for full disclaimer. |
Polypharmacy is common in frailty and multimorbidity. The STOPP/START criteria are evidence-based tools to improve prescribing safety in older adults. ✅ STOPP: identify potentially inappropriate medications. ✅ START: highlight beneficial medications that are often underprescribed.
| Medication | Reason to Stop |
|---|---|
| Digoxin | No benefit in heart failure with preserved systolic function. ⚠️ Reduce dose if eGFR <30 ml/min to avoid toxicity. |
| Thiazide diuretics | Stop if recurrent hypoNa, hypoK, hyperCa, or recent gout. |
| Loop diuretics | Not for routine hypertension. Avoid for ankle oedema without HF/CKD/CLD → use compression instead. |
| Aldosterone antagonists (spironolactone, eplerenone) | Risk of hyperkalaemia if combined with ACEI/ARB without monitoring. |
| Verapamil / Diltiazem | May worsen heart failure with reduced EF. |
| Nicorandil | Discontinue if GI or mucosal ulceration occurs. |
| ACEIs or ARBs | Stop in persistent hyperkalaemia. Avoid dual blockade (ACEI+ARB) unless under specialist advice. |
| Aspirin | Avoid long-term doses >150 mg (↑ bleeding risk). Avoid without PPI if history of ulcer. Avoid with anticoagulant unless strong indication. |
| Antiplatelet + Anticoagulant | ↑ bleeding risk in stable CAD/CVD/PAD without recent ACS/stent. |
| Warfarin / DOACs | First DVT: >6 months; First PE: >12 months → stop if no ongoing risk factors. |
| NSAIDs + Warfarin/DOAC | High risk of GI bleeding. |
| Dabigatran | Avoid if eGFR <30 ml/min → bleeding risk. |
| Rivaroxaban / Apixaban | Avoid if eGFR <15 ml/min → bleeding risk. |
| Systemic corticosteroids | Avoid for maintenance COPD (inhaled steroids safer). |
| Condition | Recommended Medication | Rationale |
|---|---|---|
| Heart failure | ACEI/ARB, beta-blocker, spironolactone (if HFrEF) | Improves survival, reduces hospitalisation. |
| Atrial fibrillation | Anticoagulant (warfarin/DOAC) if CHA₂DS₂-VASc ≥2 | Reduces stroke risk. |
| Post-MI / IHD | Statin, ACEI, beta-blocker, antiplatelet (if not contraindicated) | Secondary prevention. |
| Diabetes + proteinuria | ACEI/ARB | Renal protection. |
| Osteoporosis / fragility fracture | Bisphosphonate + calcium/Vit D | Fracture risk reduction. |
| Long-term steroids | Bisphosphonate prophylaxis | Prevent steroid-induced osteoporosis. |
| Hypertension + diabetes/CKD | ACEI/ARB | Renal & CV protection. |
| Vaccinations | Influenza, pneumococcal, shingles | Reduce infection burden in frail adults. |
| Depression | Antidepressant therapy (if persistent symptoms) | Improves mood, function, QoL. |
| Constipation | Laxative if regular opioid use | Prevent faecal impaction. |
| Falls risk | Vitamin D/calcium | Bone health, muscle strength (esp. care homes). |
| Drug Class & Examples | Prescribing Concerns |
|---|---|
| 🌼 First-generation (sedating) antihistamines
Diphenhydramine, Chlorpheniramine, Promethazine, Cyproheptadine, Clemastine, Hydroxyzine, Doxylamine |
Sedating and strongly anticholinergic → ↑ delirium, falls, urinary retention, dry mouth, constipation.
Note: Diphenhydramine may be appropriate in severe allergic reactions. |
| 💊 Antispasmodics
Dicyclomine, Hyoscyamine, Propantheline, Oxybutynin (IR), Scopolamine, Belladonna alkaloids, Clidinium |
Strong anticholinergic properties → delirium, urinary retention, constipation.
Note: Hyoscyamine, scopolamine, and belladonna may be appropriate in palliative care (secretions). |
| 📘 Tricyclic Antidepressants (TCAs)
Amitriptyline, Doxepin, Imipramine, Nortriptyline |
Avoid in elderly → sedating, strong anticholinergic, cause delirium, falls, constipation, orthostatic hypotension. |
| 🧠 Anticholinergic Anti-Parkinson Agents
Benztropine, Trihexyphenidyl |
Avoid → sedation, anticholinergic toxicity. Better alternatives exist for Parkinson’s disease and EPS prevention. |
| 💪 Muscle Relaxants
Cyclobenzaprine, Methocarbamol, Carisoprodol, Metaxalone |
Limited benefit in elderly. Cause sedation, delirium, and ↑ falls risk. |
| 😴 Benzodiazepines
Alprazolam, Lorazepam, Diazepam, Chlordiazepoxide, Clorazepate |
Avoid for delirium, sleep disorders, agitation. ↑ risk of sedation and falls.
Note: May be appropriate for alcohol/benzo withdrawal. |
| 🌙 Non-benzodiazepine Hypnotics
Zolpidem |
Similar to benzodiazepines: ↑ sedation, delirium, falls, fractures. Avoid in elderly. |
| 🧩 Antipsychotic Agents (Atypical & Conventional)
Haloperidol, Thioridazine, Chlorpromazine, Olanzapine, Quetiapine, Risperidone |
↑ Risk of stroke & death in elderly with dementia. Use only if non-drug measures fail and patient is at risk to self/others. |
| ⬇️ Alpha-1 Blockers
Doxazosin, Prazosin, Terazosin |
Avoid as antihypertensives → high risk of orthostatic hypotension. Better agents available. |
| 🩺 CNS-acting Alpha Agonists
Clonidine, Methyldopa |
Associated with bradycardia, hypotension, sedation, delirium, depression. Avoid methyldopa; use clonidine cautiously. |
| ❤️ Cardiac Glycosides
Digoxin (>0.125 mg/day) |
Higher doses ↑ toxicity risk in elderly due to reduced renal clearance. No additional benefit at high doses. |
| 💓 Antiarrhythmic Drugs
Amiodarone, Flecainide, Procainamide, Sotalol, Quinidine, Disopyramide |
Rate control often safer than rhythm control in elderly. Amiodarone → thyroid/lung toxicity, QT prolongation. Disopyramide → HF, anticholinergic. |
| 💊 Non-COX Selective NSAIDs
Aspirin (>325 mg/day), Ibuprofen, Naproxen, Piroxicam, Indomethacin |
↑ GI bleeding, renal impairment, and HF exacerbation risk. If unavoidable, add PPI for gastroprotection. |
| 🍬 Long-acting Sulfonylureas
Chlorpropamide, Glyburide |
↑ Risk of prolonged hypoglycaemia. Avoid in elderly. |
| 🧪 Urinary Anti-infective Agent
Nitrofurantoin |
Avoid if CrCl <60 ml/min → ineffective & ↑ neuropathy, hepatotoxicity risk. |
💡 Take-home: Safe prescribing in geriatrics = balance between stopping harm and starting benefit. Think of STOPP/START as your structured checklist during a CGA medication review.